Purpose To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that
inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the most common …

The prototypic head and neck squamous cell carcinoma (HNSCC) arises from the mucosal
lining of the upper aerodigestive tract, demonstrates squamous differentiation …

Purpose Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck
results in median progression-free survival (PFS) of 2 months. These cancers are rich in …

While a large proportion of patients presenting with stage I and II squamous cell carcinoma
of the head and neck (SCCHN) will remain disease free after single modality treatment, the …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family
that is abnormally activated in many epithelial tumors. Several mechanisms lead to the …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Purpose High epidermal growth factor receptor (EGFR) gene copy number is associated
with poor prognosis in lung cancer, but such findings have not been reported for HNSCC. A …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the
HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to …

The development of a number of different solid tumours is associated with over-expression
of ErbB1, or the epidermal growth factor receptor (EGFR), and this over-expression is often …